Percutaneous coronary intervention with adjunctive abciximab and clopidogrel in a patient with chronic idiopathic thrombocytopaenic purpura.
The use of the antiplatelet agents abciximab and clopidogrel is now accepted therapy in percutaneous coronary intervention. We present a case in which these agents were used in a patient with idiopathic thrombocytopaenic purpura and a platelet count of 40x10(9)/l undergoing primary multivessel coronary stenting. This case shows that unstable coronary syndromes can occur in patients with thrombocytopaenia and that antiplatelet agents may be used safely in this context.
Segal
Oliver R
OR
Department of Cardiology, London Chest Hospital, London, UK.
Baker
Christopher SR
CS
Banim
Seamus
S